Pertuzumab and trastuzumab: the rationale way to synergy

It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anais da Academia Brasileira de Ciências
Hauptverfasser: Sandrine Richard, Frédéric Selle, Jean-Pierre Lotz, Ahmed Khalil, Joseph Gligorov, Daniele G. Soares
Format: Artigo
Sprache:Inglês
Veröffentlicht: Academia Brasileira de Ciências 2016
Schlagworte:
Multidisciplinaria (Ciencias Naturales y Exactas)
HER2
pertuzumab
trastuzumab
dimerization
Breast cancer
Online Zugang:https://www.redalyc.org/articulo.oa?id=32746362012
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge